Aurinia Pharmaceuticals to Present New LUPKYNIS Data on Lupus Nephritis at ACR and ASN Conferences
Author: Benzinga Newsdesk | October 15, 2025 06:02am
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS® (voclosporin) at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24–29, and the American Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston, TX, November 5–9.
At ACR Convergence 2025, posters include:
- Title: Real-world Effectiveness and Usage of Voclosporin: Data from the ENLIGHT-LN Registry
Presenting Author: Leanna Wise, M.D., Keck School of Medicine of USC - Title: Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Sources
Presenting Author:Eugenia Chock, M.D., M.P.H., Yale School of Medicine
At ASN Kidney Week 2025, posters include:
- Title: Non-equilibrium Voclosporin Disposition Following IV and PO Administration: Tissue Levels in Kidney, Liver, Pancreas, and Heart Distinct from Plasma Drug Levels and Dependent on Route of Administration
Presenter: Ernie Yap, M.D., Senior Medical Director at Aurinia - Title: Voclosporin Distribution and Clearance from the Kidney and Cellular Location Following Co-administration with Ketoconazole and Rifampin
Presenter: Ernie Yap, M.D., Senior Medical Director at Aurinia - Title: Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the ENLIGHT-LN Registry
Presenting Author: Mohammad Kamgar, M.D., David Geffen School of Medicine at UCLA
Posted In: AUPH